US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

9.14

+0.06000.66%

Post-market: 9.250.1100+1.20%19:30 EDT

Volume:338.52K

Turnover:3.09M

Market Cap:731.10M

PE:-1.56

High:9.36

Open:9.10

Low:8.80

Close:9.08

52wk High:14.87

52wk Low:7.00

Shares:79.99M

Float Shares:35.75M

Volume Ratio:1.14

T/O Rate:0.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.8439

EPS(LYR):-4.3039

ROE:-81.92%

ROA:-47.10%

PB:2.26

PE(LYR):-2.12

Loading ...

Overview Company News Filings

BridgeBio Oncology Therapeutics Inc: Cash Runway Expected to Fund Operations Into 2028

THOMSON REUTERS

Bbot Reports First Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS

Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66

BridgeBio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology initiated with a Buy at Canaccord

BridgeBio Oncology Initiated at Buy by Canaccord Genuity

Canaccord Genuity Initiates BridgeBio Oncology Therapeutics at Buy

MT Newswires Live

BridgeBio Oncology Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

BridgeBio Oncology Therapeutics’ Principal Accounting Officer Marc Cobo files Form 3 ownership statement

BridgeBio Oncology Therapeutics COO Idan Elmelech files initial beneficial ownership statement

BridgeBio Oncology Therapeutics announces annual shareholder meeting via webcast

Analysts Conflicted on These Healthcare Names: BridgeBio Oncology Therapeutics (BBOT), Sanofi (OtherSNYNF) and Molina Healthcare (MOH)

BridgeBio Oncology expects updated Phase 1 data for KRAS inhibitor BBO-11818 in H2 2026

BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO

BridgeBio Oncology names Pedro Beltran CEO in leadership reshuffle

Press Release: BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

BridgeBio Oncology presents preclinical AACR data for PI3Kα breaker BBO-10203

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BBOT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":9.14,"timestamp":1787601600000,"preClose":9.08,"halted":0,"volume":338518,"hourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.14,"latestTime":"19:30 EDT","volume":7478,"amount":68439.12,"timestamp":1787614207210,"change":0.11,"changeRate":0.012035,"amplitude":0.012035},"delay":0,"changeRate":0.006607929515418557,"floatShares":35752400,"shares":79988687,"eps":-5.843879,"marketStatus":"Closed","change":0.06,"latestTime":"08-24 16:00:00 EDT","open":9.1,"high":9.3575,"low":8.8,"amount":3089191.70893,"amplitude":0.061399,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.843879,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":9.08,"preHourTrading":{"tag":"盘前","latestPrice":9.14,"preClose":9.08,"latestTime":"09:02 EDT","volume":12,"amount":109.80000000000001,"timestamp":1787576550596,"change":0.06,"changeRate":0.006608,"amplitude":0.002203},"postHourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.14,"latestTime":"19:30 EDT","volume":7478,"amount":68439.12,"timestamp":1787614207210,"change":0.11,"changeRate":0.012035,"amplitude":0.012035},"volumeRatio":1.139074},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":35752400,"roa":"-47.10%","roe":"-81.92%","lyrEps":-4.3039,"volumeRatio":1.139074,"shares":79988687,"dividePrice":0,"high":9.3575,"amplitude":0.061399,"preClose":9.08,"low":8.8,"week52Low":7,"pbRate":"2.26","week52High":14.87,"institutionHeld":0,"latestPrice":9.14,"eps":-5.843879,"divideRate":0,"volume":338518,"delay":0,"ttmEps":-5.843879,"open":9.1,"prevYearClose":12.52,"prevWeekClose":9.08,"prevMonthClose":8.09,"prevQuarterClose":7.62,"fiveDayClose":9.04,"twentyDayClose":8.75,"sixtyDayClose":8.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BBOT","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-05-12","symbol":"BBOT","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.53},{"market":"US","date":"2026-03-05","symbol":"BBOT","fiscalQuarterEnding":"2025/12","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.6364,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1783742400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2026-08-21","current":-1.56403,"percent":0.948413,"low":-11.944957,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"high":-3.70137,"avg":-7.183327,"sd":2.49794,"marketCap":727982344},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621},{"date":"2025-12-26","current":-8.490629,"twenty":-11.051335,"median":-9.938056,"eighty":-8.720294,"marketCap":975861981},{"date":"2026-01-02","current":-8.713334,"twenty":-11.00789,"median":-9.919954,"eighty":-8.650698,"marketCap":1001458361},{"date":"2026-01-09","current":-9.256178,"twenty":-10.960825,"median":-9.809862,"eighty":-8.597806,"marketCap":1063849537},{"date":"2026-01-16","current":-8.003462,"twenty":-10.901088,"median":-9.61327,"eighty":-8.567184,"marketCap":919869900},{"date":"2026-01-23","current":-7.829474,"twenty":-10.885701,"median":-9.557912,"eighty":-8.530995,"marketCap":899872728},{"date":"2026-01-30","current":-8.699415,"twenty":-10.880305,"median":-9.521034,"eighty":-8.553265,"marketCap":999858587},{"date":"2026-02-06","current":-7.063925,"twenty":-10.867923,"median":-9.470009,"eighty":-8.485061,"marketCap":811885173},{"date":"2026-02-13","current":-7.947786,"twenty":-10.83411,"median":-9.398729,"eighty":-8.38554,"marketCap":913470805},{"date":"2026-02-20","current":-7.043047,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"marketCap":809485512},{"date":"2026-02-27","current":-7.13352,"twenty":-10.763512,"median":-9.179623,"eighty":-8.144045,"marketCap":819884041},{"date":"2026-03-06","current":-6.882977,"twenty":-10.695084,"median":-9.036987,"eighty":-8.006246,"marketCap":791088114},{"date":"2026-03-13","current":-5.451193,"twenty":-10.678337,"median":-8.936039,"eighty":-7.945698,"marketCap":730699673},{"date":"2026-03-20","current":-5.403428,"twenty":-10.588779,"median":-8.821207,"eighty":-7.854528,"marketCap":724297048},{"date":"2026-03-27","current":-5.510899,"twenty":-10.477499,"median":-8.762051,"eighty":-7.489849,"marketCap":738702956},{"date":"2026-04-02","current":-5.391486,"twenty":-10.453966,"median":-8.733947,"eighty":-7.421645,"marketCap":722696391},{"date":"2026-04-10","current":-5.287,"twenty":-10.379747,"median":-8.713334,"eighty":-7.088979,"marketCap":708690647},{"date":"2026-04-17","current":-5.504928,"twenty":-10.361645,"median":-8.657658,"eighty":-7.020776,"marketCap":737902628},{"date":"2026-04-24","current":-5.355662,"twenty":-10.30763,"median":-8.605462,"eighty":-6.799463,"marketCap":717894422},{"date":"2026-05-01","current":-5.021307,"twenty":-10.25963,"median":-8.567184,"eighty":-5.98855,"marketCap":673076041},{"date":"2026-05-08","current":-4.692922,"twenty":-10.225879,"median":-8.553265,"eighty":-5.587323,"marketCap":629057988},{"date":"2026-05-15","current":-4.419866,"twenty":-10.182434,"median":-8.490629,"eighty":-5.506122,"marketCap":681079323},{"date":"2026-05-22","current":-4.73149,"twenty":-10.167401,"median":-8.47671,"eighty":-5.429101,"marketCap":729099017},{"date":"2026-05-29","current":-4.595521,"twenty":-10.107271,"median":-8.403635,"eighty":-5.355662,"marketCap":708146799},{"date":"2026-06-05","current":-4.278409,"twenty":-10.091924,"median":-8.379277,"eighty":-5.319839,"marketCap":659281465},{"date":"2026-06-12","current":-3.878121,"twenty":-10.077631,"median":-8.309681,"eighty":-5.287,"marketCap":597598995},{"date":"2026-06-18","current":-3.992489,"twenty":-10.053919,"median":-8.201809,"eighty":-5.246997,"marketCap":615222558},{"date":"2026-06-26","current":-3.997687,"twenty":-9.989006,"median":-8.066098,"eighty":-5.177737,"marketCap":616023629},{"date":"2026-07-02","current":-4.054871,"twenty":-9.965147,"median":-8.010422,"eighty":-5.018919,"marketCap":624835411},{"date":"2026-07-10","current":-4.725485,"twenty":-9.946462,"median":-7.965184,"eighty":-4.959212,"marketCap":728173575},{"date":"2026-07-17","current":-4.319998,"twenty":-9.932881,"median":-7.944306,"eighty":-4.729088,"marketCap":665690034},{"date":"2026-07-24","current":-4.533138,"twenty":-9.923745,"median":-7.895589,"eighty":-4.678698,"marketCap":698533946},{"date":"2026-07-31","current":-4.41877,"twenty":-9.900032,"median":-7.829474,"eighty":-4.589283,"marketCap":680910384},{"date":"2026-08-07","current":-4.56433,"twenty":-9.857488,"median":-7.544133,"eighty":-4.574377,"marketCap":703340373},{"date":"2026-08-14","current":-4.060031,"twenty":-9.815588,"median":-7.439739,"eighty":-4.568002,"marketCap":739388569},{"date":"2026-08-21","current":-3.997399,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"marketCap":727982344}],"updateTime":1787617312855},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635047228","title":"BridgeBio Oncology Therapeutics Inc: Cash Runway Expected to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2635047228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635047228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9SLMNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635022804","title":"Bbot Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635022804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635022804?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619811,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9SLMNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223869","title":"Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223869?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619780,"startTime":"0","endTime":"0","summary":"-- Announced encouraging preliminary safety and efficacy data across all. -- Announced publication in Cancer Discovery highlighting preclinical data. demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor. -- Clinical readouts expected in the second half of 2026 across all three. -- Cash runway expected to fund operations into 2028. SOUTH SAN FRANCISCO, Calif., May 12, 2026  -- BridgeBio Oncology Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3K<ALPHA> activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppressi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","LU2360107325.USD","LU1861214812.USD","LU1548497426.USD","ORR","IE00BZ199S13.USD","CRC","LU1854103824.USD","BK4588","BK4211","IE00BFMHRM44.USD","LU2065732104.USD","LU1861219969.SGD","BBOT","PFS","BK4097","ON","LU1854104046.USD","LU1978683503.SGD","IE00BD6J9T35.USD","LU1720051017.SGD","LU2298322129.HKD","BK4195","PR","BK4605","LU0456854461.SGD","BK4512","LU1861215975.USD","LU1861220033.SGD","LU0348723411.USD","BK4141","BK4139","BK4213","LU0124384867.USD","LU0266512127.USD","LU1720051108.HKD","BK4585","PRGS","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635924796","title":"BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2635924796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635924796?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616536,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics awarded inducement equity compensation on May 10, 2026 to one employee hired in March 2026.Grant comprised non-qualified stock options covering 32,675 shares, struck at USD 7.66 per share.Vesting set at 25% on first anniversary of start date, remaining portion in 36 equal monthly installments, contingent on continued service.Awards issued under company’s 2025 Inducement Plan, adopted in October 2025, outside stockholder-approved equity incentive plans.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2hzXdL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","NDAQ","BK4505","BBOT","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BBIO","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635924782","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635924782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635924782?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA2RCLW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240680","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240680?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"Investor Contact:. Heather Armstrong, Head of Investor Relations. Investors@BBOTx.com. Media Contact:. Jake Robison. Inizio Evoke Comms. Jake.robison@inizioevoke.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293368/0/en/BridgeBio-Oncology-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634282843","title":"BridgeBio Oncology initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2634282843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634282843?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:08","pubTimestamp":1778504936,"startTime":"0","endTime":"0","summary":"Canaccord initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target The company is developing RAS inhibitors positione...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634286100","title":"BridgeBio Oncology Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286100","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286100?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 08:00 ET (12:00 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634569286","title":"Canaccord Genuity Initiates BridgeBio Oncology Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2634569286","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634569286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:59","pubTimestamp":1778500746,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics (BBOT) has an average rating of buy and mean price target of $25.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","BBOT","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633092726","title":"BridgeBio Oncology Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633092726","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633092726?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:33","pubTimestamp":1778016786,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview BridgeBio Oncology Therapeutics Inc BBOT.OQ BBOT.O is expected to  report resultson May 7 (estimated) ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I3K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4139","BBOT","BBIO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632266940","title":"BridgeBio Oncology Therapeutics’ Principal Accounting Officer Marc Cobo files Form 3 ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2632266940","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632266940?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:35","pubTimestamp":1777581341,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics principal accounting officer Marc Cobo filed an initial Form 3 disclosing 5,431 common shares.Filing also reported stock options covering 154,215 shares with exercise prices of $9.59-$10.19.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbYjJQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBOT","BBIO","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669153","title":"BridgeBio Oncology Therapeutics COO Idan Elmelech files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669153","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669153?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:31","pubTimestamp":1777581078,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics COO, principal financial officer Idan Elmelech filed Form 3 reporting 14,838 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL67007x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BBOT","BK4505","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631535570","title":"BridgeBio Oncology Therapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631535570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631535570?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:15","pubTimestamp":1777407324,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics will hold 2026 annual stockholders meeting June 16, 2026 in virtual format.Stockholders will vote on election of two Class I directors, with nominees Frank McCormick and Peter Lebowitz.Meeting agenda also includes ratification of Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLztZcd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629523853","title":"Analysts Conflicted on These Healthcare Names: BridgeBio Oncology Therapeutics (BBOT), Sanofi (OtherSNYNF) and Molina Healthcare (MOH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629523853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629523853?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:40","pubTimestamp":1776955211,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BridgeBio Oncology Therapeutics (BBOT), Sanofi (SNYNF) and Molina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-oncology-therapeutics-bbot-sanofi-othersnynf-and-molina-healthcare-moh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-oncology-therapeutics-bbot-sanofi-othersnynf-and-molina-healthcare-moh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MOH","LABU","SG9999014005.SGD","SNYNF","XBI","XLV","BK4154","SG9999014013.SGD","BK4532","SG9999014039.USD","BK4581","BK4585","BK4007","BBOT","BK4139","SG9999014021.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629736010","title":"BridgeBio Oncology expects updated Phase 1 data for KRAS inhibitor BBO-11818 in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629736010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629736010?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:56","pubTimestamp":1776891396,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics presented new preclinical data at AACR 2026 for BBO-11818, an oral pan-KRAS inhibitor designed to target KRAS in both active and inactive states.Results showed broad anti-tumor activity across KRAS-mutant models, supporting potential use as monotherapy.Combination studies indicated stronger anti-tumor effects when paired with BBO-10203, cetuximab, or anti-PD-1, positioning BBO-11818 as a potential backbone for combination regimens.Updated Phase 1 clinical data are expected in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL41t5Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4505","BBOT","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629004081","title":"BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629004081","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629004081?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:09","pubTimestamp":1776866982,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (BBOT) announced the appointment of Pedro Beltran as CEO and Idan Elmelech as COO effective April 20. This transition reflects B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-appoints-pedro-beltran-as-ceo-idan-elmelech-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-appoints-pedro-beltran-as-ceo-idan-elmelech-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT","BK4588","LU1992135472.HKD","BK4585","COO","GB00BDT5M118.USD","BK4139","LU2272731600.USD","LU2272731782.SGD","BK4198","LU1992135399.USD","LU2211815571.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629441041","title":"BridgeBio Oncology names Pedro Beltran CEO in leadership reshuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=2629441041","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629441041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:00","pubTimestamp":1776862833,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics named Pedro J. Beltran chief executive officer, effective April 20, 2026.Beltran previously served as BBOT chief scientific officer, joining BridgeBio in 2020 as senior vice president of biology.Elmelech previously served as senior vice president of strategy and business development, with remit spanning finance and accounting, corporate strategy, operations, business development.Board appointed Neil Kumar executive chairman; former CEO Eli Wallace will move to senior adviser role.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2Y6wcX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","NDAQ","BBOT","BBIO","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4505","BK4139","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041902","title":"Press Release: BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041902","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041902?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:00","pubTimestamp":1776862800,"startTime":"0","endTime":"0","summary":"Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development. Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide the company as it embarks on its next stage of development. Former CEO, Eli Wallace, PhD, will serve as a Senior Adviser to the company, continuing to leverage his scientific expertise and deep understanding of BBOT's programs to support the company going forward. Dr. Beltran brings decades of experience in oncology drug development including 20 years with large pharmaceutical companies. Dr. Beltran joined BridgeBio Pharma in 2020 as Senior Vice President of Biology and became Chief Scientific Officer of BBOT in July 2023. Prior to BridgeBio, Dr. Beltran was Senior Vice Pr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629336065","title":"BridgeBio Oncology presents preclinical AACR data for PI3Kα breaker BBO-10203","url":"https://stock-news.laohu8.com/highlight/detail?id=2629336065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629336065?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:30","pubTimestamp":1776807041,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics presented new preclinical data at AACR 2026 on BBO-10203, an experimental therapy targeting RAS-driven PI3Kα-AKT signaling.Data showed pathway inhibition in HER2-amplified models without the metabolic side effect commonly associated with PI3K inhibition.Studies also indicated stronger anti-tumor activity when combined with HER2 therapies such as tucatinib or trastuzumab in animal models.Updated clinical data for BBO-10203 are expected in second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL6BrBQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","NDAQ","BBOT","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629394065","title":"BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629394065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629394065?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:30","pubTimestamp":1776807000,"startTime":"0","endTime":"0","summary":"BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278572/0/en/BBOT-Presents-Preclinical-Data-Showing-RAS-PI3K%CE%B1-Breaker-BBO-10203-Inhibits-PI3K%CE%B1-AKT-Signaling-in-HER2AMP-Models-at-the-AACR-Annual-Meeting-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}]}}